JPWO2022125967A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022125967A5 JPWO2022125967A5 JP2023560240A JP2023560240A JPWO2022125967A5 JP WO2022125967 A5 JPWO2022125967 A5 JP WO2022125967A5 JP 2023560240 A JP2023560240 A JP 2023560240A JP 2023560240 A JP2023560240 A JP 2023560240A JP WO2022125967 A5 JPWO2022125967 A5 JP WO2022125967A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- mek inhibitor
- daily
- selectively inhibits
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124647 MEK inhibitor Drugs 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 5
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims 2
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims 2
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 claims 2
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims 2
- 229960004066 trametinib Drugs 0.000 claims 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical group CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- SUDAHWBOROXANE-VIFPVBQESA-N PD 0325901-Cl Chemical compound OC[C@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-VIFPVBQESA-N 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229950003054 binimetinib Drugs 0.000 claims 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims 1
- 229960002271 cobimetinib Drugs 0.000 claims 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229950010746 selumetinib Drugs 0.000 claims 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124663P | 2020-12-11 | 2020-12-11 | |
| US202063124667P | 2020-12-11 | 2020-12-11 | |
| US202063124671P | 2020-12-11 | 2020-12-11 | |
| US202063124674P | 2020-12-11 | 2020-12-11 | |
| US63/124,674 | 2020-12-11 | ||
| US63/124,667 | 2020-12-11 | ||
| US63/124,663 | 2020-12-11 | ||
| US63/124,671 | 2020-12-11 | ||
| PCT/US2021/062921 WO2022125967A2 (en) | 2020-12-11 | 2021-12-10 | Combination therapies for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023553533A JP2023553533A (ja) | 2023-12-21 |
| JPWO2022125967A5 true JPWO2022125967A5 (https=) | 2024-12-17 |
| JP2023553533A5 JP2023553533A5 (https=) | 2024-12-17 |
Family
ID=81974875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560240A Pending JP2023553533A (ja) | 2020-12-11 | 2021-12-10 | 癌の処置のための併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240058352A1 (https=) |
| EP (1) | EP4259638A4 (https=) |
| JP (1) | JP2023553533A (https=) |
| KR (1) | KR20230152652A (https=) |
| AU (1) | AU2021396397A1 (https=) |
| CA (1) | CA3201654A1 (https=) |
| WO (1) | WO2022125967A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022125971A1 (en) * | 2020-12-11 | 2022-06-16 | Erasca, Inc. | Combination therapies for the treatment of cancer |
| US20240285624A1 (en) * | 2021-06-24 | 2024-08-29 | Erasca, Inc. | Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy |
| WO2023059771A1 (en) * | 2021-10-06 | 2023-04-13 | Erasca, Inc. | Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| TW202440128A (zh) * | 2023-01-06 | 2024-10-16 | 美商艾瑞斯卡公司 | Raf抑制劑及erk1/2及/或shp2抑制劑組合療法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016341445B2 (en) * | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| CA3074690A1 (en) * | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| JP7542538B2 (ja) * | 2018-09-18 | 2024-08-30 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体 |
| PH12021551949A1 (en) * | 2019-02-12 | 2022-07-18 | Janssen Pharmaceutica Nv | Cancer treatment |
-
2021
- 2021-12-10 JP JP2023560240A patent/JP2023553533A/ja active Pending
- 2021-12-10 CA CA3201654A patent/CA3201654A1/en active Pending
- 2021-12-10 WO PCT/US2021/062921 patent/WO2022125967A2/en not_active Ceased
- 2021-12-10 KR KR1020237023401A patent/KR20230152652A/ko not_active Abandoned
- 2021-12-10 AU AU2021396397A patent/AU2021396397A1/en not_active Abandoned
- 2021-12-10 EP EP21904512.7A patent/EP4259638A4/en not_active Withdrawn
- 2021-12-10 US US18/256,090 patent/US20240058352A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022121594A5 (https=) | ||
| CN101001623B (zh) | 抗癌效果增强剂 | |
| Silverman Jr et al. | Epidemiologic and demographic update in oral cancer: California and national data—1973 to 1985 | |
| Vogl et al. | Diagnostic significance of pulmonary hypertrophic osteoarthropathy | |
| Travis et al. | Sweet's syndrome: an unusual cutaneous feature of Crohn's disease or ulcerative colitis | |
| JP2008528671A5 (https=) | ||
| JP2024178159A5 (https=) | ||
| De Vos et al. | Piroxicam and carboplatin as a combination treatment of canine oral non‐tonsillar squamous cell carcinoma: a pilot study and a literature review of a canine model of human head and neck squamous cell carcinoma | |
| JP2021080296A5 (https=) | ||
| Kumar et al. | Primary malignant melanoma of oral cavity: A tertiary care center experience | |
| Wu et al. | Effective eradication of oral verrucous carcinoma with continuous intraarterial infusion chemotherapy | |
| Mascarenhas et al. | Recurrent metastatic renal cell carcinoma presenting as a bleeding gastric ulcer after a complete response to high-dose interleukin-2 treatment | |
| JPWO2022125967A5 (https=) | ||
| JP2021105005A5 (https=) | ||
| JPWO2021222278A5 (https=) | ||
| JP2008525493A5 (https=) | ||
| Bolcal et al. | Comparison of magnesium sulfate with opioid and NSAIDs on postoperative pain management after coronary artery bypass surgery | |
| Culver et al. | Eosinophilic gastritis | |
| CN107519152A (zh) | 一种口腔溃疡膜及其制备方法 | |
| JPWO2022125971A5 (https=) | ||
| Schimmel et al. | Resolution of Pulmonary: Lymphangitic Carcinoma of the Breast | |
| JPWO2020061458A5 (https=) | ||
| Lee et al. | Neither dopamine nor dobutamine corrects mesenteric blood flow depression caused by positive end-expiratory pressure in a rat model of acute lung injury | |
| Chandran et al. | Carcinoma esophagus with small bowel metastasis: a case report with review of literature | |
| Cusan et al. | An early twentieth-century case of lower lip cancer from the Morgagni Museum (Padua, Italy) |